Precision BioSciences to Report First Quarter 2023 Results on May 9, 2023

DURHAM, N.C.--(BUSINESS WIRE)--May 2, 2023--

Precision BioSciences, Inc. (DTIL" href="/company/DTIL" onmouseover="handlePagePreview('company','DTIL')" style="color:#4007a2 !important; text-decoration:underline !important; font-weight:bold;">Nasdaq: DTILDTIL-pp">), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the first quarter 2023 and provide a business update on May 9, 2023.

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company’s pipeline consists of multiple “off-the-shelf” CAR T immunotherapy clinical candidates and several in vivo gene editing therapy candidates designed to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences please visit www.precisionbiosciences.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20230502005091/en/

CONTACT: Investor and Media Contact:

Mei Burris

Director, Investor Relations and Finance

Mei.Burris@precisionbiosciences.com

KEYWORD: NORTH CAROLINA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: HEALTH HEALTH TECHNOLOGY GENETICS GENERAL HEALTH CLINICAL TRIALS PHARMACEUTICAL BIOTECHNOLOGY

SOURCE: Precision BioSciences, Inc.

Copyright Business Wire 2023.